










The Centre for Health Economics Research and Evaluation (CHERE) was 
established in 1991.  CHERE is a centre of excellence in health economics and 
health services research. It is a joint Centre of the Faculties of Business 
and Nursing, Midwifery and Health at the University of Technology, Sydney, in 
collaboration with Central Sydney Area Health Service. It was established as a 
UTS Centre in February, 2002. The Centre aims to contribute to the development 
and application of health economics and health services research through 
research, teaching and policy support. CHERE’s research program encompasses 
both the theory and application of health economics. The main theoretical 
research theme pursues valuing benefits, including understanding what 
individuals value from health and health care, how such values should be 
measured, and exploring the social values attached to these benefits. The 
applied research  focuses on economic and the appraisal of new programs or new 
ways of delivering and/or funding services. CHERE’s teaching includes 
introducing clinicians, health services managers, public health professionals 
and others to health economic principles. Training programs aim to develop 
practical skills in health economics and health services research. Policy 
support is provided at all levels of the health care system by undertaking 
commissioned projects, through the provision of formal and informal advice as 
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Background: As the population ages, the incidence of dementia and its burden on society 
will increase. The economic costs of dementia are high, particularly for persons in the 
mid and late stages of the disease, when formal care arrangements such as nursing home 
placement are required. The need for care is often precipitated by the development of 
behavioural and psychological symptoms of dementia (BPSD) which also severely affect 
the quality of life of affected persons and their carers  The Caring for Aged-Care 
REsident Study (CARES), the first randomised controlled trial to evaluate Dementia Care 
Mapping (DCM) and Person Centred Care (PCC), demonstrated that either of the two 
interventions improved outcomes compared to Usual Care (UC) on the primary outcome 
measure, the Cohen-Mansfield Agitation Inventory (CMAI). This study reports the 
results of an economic evaluation which was undertaken in conjunction with the trial. 
This information will provide additional information to assist policy makers in making 
choices between competing options. 
 
Methods: Fifteen nursing homes were randomised to one of three conditions: DCM, PCC 
or Usual Care (UC).  The sample consisted of 360 residents with dementia. Data were 
collected at baseline, three months, and eight months by assessors blind to group 
assignment. In addition to the CMAI, data were collected about the use and costs of 
health care resources and pharmacological interventions. Total costs associated with each 
of the interventions were estimated, which were contrasted with the outcomes using 
standard health economics methodology.  
 
Results: Over one year, the cost per residential setting of implementing DCM and PCC 
relative to UC was $10,034 and $2,250 respectively. The additional cost per resident-
level unit improvement in CMAI post-intervention (at follow-up) relative to UC was 
$48.95 ($46.89) for DCM and $8.01 ($6.43) for PCC. Compared to DCM, PCC produced 
a greater reduction in anxiety and agitation at a lower cost. Therefore, DCM was 
dominated by PCC and removed from the economic evaluation. Sensitivity analysis 
suggests this result is robust to changing model parameters.    
 
Conclusions: PCC provides a greater decrease in agitation and related behavioural and 
psychological symptoms of dementia, compared with DCM, at a lower cost and is the 
preferred option for cost-effectiveness. While there is no existing standard for a 
reasonable cost for a point improvement in CMAI, the cost per unit under PCC seems 
acceptable. 
 
Trial registration: The clinical trial used in the evaluation is registered as Australian 




By 2030 the number of Australians aged 65 years or more is expected to increase to 
over six million, of which 944,000 are expected to be aged over 85.[1] This represents 
a 108% and a 154% increase respectively from 2008 figures.[1] The Australian 
Institute of Health and Welfare estimates that the number of people with dementia 
will increase from 175,000 in 2003 to 465,000 in 2031.[2] With the increasing 
prevalence of dementia, health care costs associated with the condition are predicted 
to increase by 225% between 2003 and 2030/1.[2]  
 
The presence of behavioural and psychological symptoms of dementia (BPSD) 
including agitation, aggression, resistance to care, hallucinations and delusions, are 
often the main reason (or a significant contributory factor) for the admission of 
persons with dementia to residential care [3]. Both pharmacological and behavioural 
management techniques are used to assist in managing and minimising BPSD [4] 
although behavioural techniques are more labour intensive. One of the issues faced by 
the health care system is how to maintain acceptable standards of care and quality of 
life for persons with dementia in the context of finite resources [5] 
 
There is a significant association between dementia severity and the annual costs of 
the disease, with costs increasing as the disease progresses. Direct costs include 
prescribed medications [2, 3] specialist medical consultations and non-medical 
services, such as respite and residential care. Indirect costs associated with increasing 
severity include changes in care worker productivity, increased absences from work 
and decreased caring ability as well as intangible costs, such as distress and lowered 
quality of life in persons with dementia and their caregivers. 
 
Individually tailored behavioural interventions have been identified as the most 
promising way of supporting a persons’ quality of life [6]. However, as the residential 
care sector is staffed mainly by people without specialist dementia care training, their 
ability to incorporate behavioural techniques into day-to-day care is limited Two 
accessible  approaches to care are Dementia Care Mapping (DCM) and Person 
Centred Care (PCC). However, as both require significant levels of staff training and 
follow-up it is important to assess the extent to which the additional costs associated 
  
with such programs can be justified in terms of improved behavioural outcomes for 
patients. This paper reports the results of an economic evaluation of the Caring for 
Aged-Care REsident Study (CARES), a cluster-randomised trial, which investigated 
the relative effectiveness of DCM, PCC and Usual Care (UC). 
 
Person-Centred Care, both as a philosophy and a method of care, is based on the 
social-psychological theory of personhood in dementia.[7] This approach recognises 
the persistence of “personhood” despite other losses occurring in dementia, hence 
achieving well-being is a central focus of care. Kitwood proposed that the care 
environment must not only be informed by a person’s clinical history but also the 
person’s social and functional history, and be designed to cultivate the retention of 
capacities by enhancing remaining strengths rather than managing deficits. PCC 
methodology prescribes individualised care planning informed by the person’s 
history, needs and preferences, material and management environments that reflect 
the principles described above, and care staff who are sensitised to the person’s 
unique personality and preferences, able to interpret responses and behaviours and 
adjust care practices accordingly. PCC has been implemented most successfully in 
residential aged care for persons with dementia. In particular, it has been shown to 
reduce the use of physical and chemical restraints to manage behavioural 
disturbance.[8] 
 
Dementia Care Mapping (DCM), which was developed by the Dementia Research 
Group at Bradford University (UK), also aims to assist staff in identifying and 
addressing factors which impact on the well-being of the person with dementia based 
on the philosophy of PCC [7].When DCM is used as a vehicle for closely analysing 
and correcting contextual factors which stimulate ill-being for the person with 
dementia, it has been shown to assist staff significantly to reduce the triggers for 
behavioural disturbance. It is also an effective education vehicle for introducing 
person-centred care in any formal care setting.[9] DCM entails specially-trained staff 
making continuous and systematic observations of residents going about their daily 
life for 6-8 hours, to identify factors associated with their expressions of both well-
being and ill-being. These observations are carefully documented and scored and are 
fed back to care staff, with the aim of assisting them to devise person-centred care 
  
plans and strategies that aim to improve well-being and reduce ill-being in the person 
with dementia. These strategies are then implemented and monitored regularly. The 
process has merit and is gaining worldwide popularity. However, the cost of 
implementing DCM may be prohibitive for aged care providers who wish to employ 
the process to improve care quality, as it is labour intensive, training is costly and full 
supervision is required from an accredited DCM trainer.[9, 10]  
 
The CARES trial, the first to subject PCC and DCM to a randomised controlled trial, 
concluded that both PCC and DCM reduced agitation and improved quality of life 
relative to UC. However, it is unclear whether this result is adequate to justify 
economically generalised adoption of either technique. Economic evaluation is a 
potentially useful tool in this debate as it seeks to quantify both the benefits and costs 
of the approaches under consideration with the aim of identifying which intervention 
represents the better use of scarce societal resources. Generally, this means estimating 
an Incremental Cost-Effectiveness Ratio (ICER). If a new intervention is being 
compared with an existing intervention, the ICER estimated in the following way: 
 
Cost New – Cost Comparator 
Effectiveness New – Effectiveness Comparator 
ICER =  
 
The ICER can be interpreted as the cost of a one-point improvement in whichever 
outcome measure is considered to best represent the effect of the intervention. In the 
case of DCM, PCC and Usual Care (UC), the ICERs of DCM and PCC can be 
contrasted with that of UC; it is then possible to compare DCM and PCC if the results 
are likely to further inform the decision-making process. For example, it would be 
appropriate to make such a comparison if both approaches are equally effective but 
one costs less in total. In this situation, cost-effectiveness analysis would identify the 
extra resources available for use in other areas of the healthcare sector. The aims of 
the economic evaluation reported here were to estimate both the costs and 
effectiveness of DCM and PCC relative to UC within the CARES trial; to contrast the 
aggregate costs and outcomes across the three interventions and attempt to reach 
conclusions about the optimal approach; and to present the limitations and 






CARES was a cluster-randomised trial based in Sydney, Australia. Trial participants 
(n=360) were recruited from 15 residential dementia care sites across the metropolitan 
area, selected for comparative management structure, standards and size. All selected 
residents: were aged at least 60 years; were classified under the Australian Resident 
Classification Scale (RCS) at category 1-3 (RCS determines level of care required for 
individual residents, ranging between 1-8, 1 being most dependent); and provided 
consent to participate in the trial directly or by proxy from their guardian or person 
responsible. Exclusion criteria were serious co-morbidities likely to complicate or 
mask dementia and/or receipt of palliative care. 
 
The breakdown of units by intervention allocation, resident and staff numbers is 
shown in Figure 1. 
 
  





DCM training was provided by two Bradford University-accredited trainers to two 
nurses/care staff for each of the five DCM sites. The authors (LC and Y-HJ) who 
were trained and experienced in the DCM techniques (also called mappers) conducted 
DCM mapping alongside the DCM trained nurses/care staff at each site for six 
continuous hours on two consecutive days and  recorded observations from which a 
Well/Ill-being (WIB) score was calculated for each participating resident at each of 
the five sites. Using factors that were observed to stimulate well being and/or ill-being 
in the residents, care plans based on person-centred principles were developed by the 
mappers to provide feedback on the findings to site staff. The DCM trained staff at 
each site were then supported by LC and Y-HJ to continue encouraging site staff to 
maintain the recommended resident care plan strategies over the following four 
  
months of the study and beyond. The time spent by trained staff on DCM-related 
activities was estimated. 
 
The PCC training manual [11] was employed to provide PCC education for PCC site 
staff by one author (JS-P). This consisted of a two-day training session for two staff 
from each of the five PCC sites. In addition, PCC resource materials and two 
supervision field visits were provided at each site (over a two week period). Ongoing 
support by telephone and email was supplied and documented by JS-P. Once on-site 
training and supervision were completed, the trained staff in each site took on 
responsibility for the continued implementation of PCC. 
 
Resident-level pharmaceutical use was collected at baseline, immediately following 
the intervention (at three months) and four months following the end of the 
intervention. Information was collected about the use of antidepressant, anti-
psychotic, anxiolytic and other psychotropic medications as these are commonly 
prescribed to reduce the incidence and severity of BPSDs. The data collection detailed 
the product used, dosage and regularity of use. Pharmaceutical Benefit Schedule 
(PBS) codes were assigned to each instance of usage and multiplied by the regularity 
to provide a cost per patient per day. Since brand names were not recorded, it was 
assumed that all usage was of generic products when available. This assumption is 
unlikely to affect the relative results of the three intervention arms as there is no 
reason to believe that prescribing behaviour in this particular dimension is affected by 
training.  Differences in the average expenditure per resident both over time and 
between intervention arms were estimated. 
 
The primary study outcome, agitation (and related behavioural and psychological 
symptoms of dementia), was assessed using the Cohen-Mansfield Agitation Inventory 
(CMAI) (Cohen-Mansfield & Werner 1998) which has been used widely in dementia 
care. [12, 13] The CMAI is a 29-item tool, which assesses the level of agitation and 
related BPSDs, such as anxiety and anger responses, over the preceding seven days. 
Each item is scored between 1 (never) and 7 (several times per hour), making the 
range of scores vary from 29 to 203.  
 
  
To adjust for baseline differences, characteristics of site and residents that differed 
between the intervention groups at baseline were included in models as covariates. 
The best method for presenting ICERs in this context is uncertain. Since the CMAI is 
effectively a count variable, it was decided to present the cost per behaviour avoided 
(i.e. a cost per 1-point reduction in one individual).   
 
Since the analysis required a number of assumptions, in particular regarding the 
amount of intervention-specific time spent by each member of staff, a univariate 
sensitivity analysis was undertaken. This analysis investigated the effect of changing 
the model parameters on the baseline conclusions. Thus, the estimated time spent on 
DCM was increased and decreased by 8 hours per month to reflect uncertainty about 
the actual time spent on activities related to mapping and devising the care plan. In 
addition, the effects of increasing or decreasing the pharmacological costs by 20% in 
each of the intervention arms sequentially were analysed.  
 
The perspective employed was that of the health service. Thus, no costs accruing 
beyond the residential home were considered. Discounting was not undertaken since 
all outcomes and costs occurred in the first year. Whilst it may be of considerable 
interest to ascertain whether benefits endured beyond the study period, no evidence 
was available which allowed this to be estimated in this study. 
 
Results and Discussion 
 
The clinical outcomes will be reported fully elsewhere [14] . Briefly, levels of 
agitation and aggression as measured by the CMAI decreased in residents enrolled in 
both the PCC and DCM intervention arms compared to those in Usual Care (UC), 
more so for PCC than for DCM. Greater variability in the PCC scores after evaluation 
meant that it was not statistically significantly better than UC while DCM was. These 
results are outlined in  
Table 1. Even when corrected for the differing baseline characteristics, the significant 
interaction term remained (p=0.001). (see Figure 2).  
 
  
Table 1:  Resident mean (SE) scores for agitation, neuropsychological status
1 and 
quality of life
2, by intervention group at each time point, adjusted for covariates 
that differed at baseline
3.    
 
 Pre  Post  Follow-up  p  values
4 
Agitation (CMAI) 
DCM  46.1 (6.5)  45.1 (6.6)  43.7 (6.5)  P(Group) = 0.33 
PCC  47.5 (9.1)  41.7 (9.2)  37.2 (9.1)  P(Time)   = 0.47 
UC  50.3 (6.8)  58.7 (6.9)  57.7 (6.8)  P(G x T)  = 0.005 
Neuropsychological status (NPI) 
DCM  12.7 (5.1)  16.8 (5.1)  13.5 (5.1)  P(Group) = 0.68 
PCC  21.3 (6.8)  14.5 (6.9)  12.6 (6.9)  P(Time)   = 0.05 
UC  16.9 (5.3)  20.2 (5.4)  15.3 (5.3)  P(G x T)  = 0.30 
Quality of life (QUALID) 
DCM  23.5 (1.6)  23.4 (1.6)  24.5 (1.6)  P(Group) = 0.78 
PCC  22.7 (2.2)  21.5 (2.2)  20.8 (2.2)  P(Time)   = 0.80 
UC  23.2 (1.7)  23.7 (1.7)  24.4 (1.7)  P(G x T)  = 0.33 
1.  NPI scores: means and SE from analysis of untransformed data; p values from 
analysis of square-root transformed data, significant covariates were GDS 
(p=0.01) and RCS (p=0.02). 
2.  QUALID ; significant covariates were GDS (p=0.006) and RCS (p=0.0003). 
3.  Six covariates differed at baseline: TESS-NH safety score, QUIS positive social 
score, RCS total score, GDS score, country of birth and number of co-morbid 
diseases. 
4.  p values from hierarchical linear models with all three time points included as 
outcomes: p(Group) is for main effect of intervention, p(Time) is for main effect 
of time (over three time points) and p(GxT) is for the interaction between group 
and time.  
 
  
Figure 2: Adjusted Cohen Mansfield Agitation Inventory score by treatment 


























































Pair-wise t-tests were run on this information, investigating whether the 
pharmaceutical costs per person at a time point were statistically significantly 
different from the observed mean. In the nine pair-wise comparisons, none were 
statistically significant at the 5% level. Therefore, as the mean difference between 
  
groups was small compared with other costs in the analysis, and the association 
between costs, intervention group and time period were unclear, the differences were 
not included in the base case economic evaluation findings. 
 
The costs of training staff and ongoing activity under DCM and PCC are shown in 
Table 3. Since the pharmaceutical cost data were not significantly different between 
intervention groups, they are not listed as a cost difference (this issue will be 
investigated in the sensitivity analysis). Costs associated with critical incidents, or 
general doctor time were not included as there was uncertainty regarding the 
comparability of data collection methods in these areas. 
 
  
Table 3: The Cost Per Site of PCC and DCM relative to UC 
 
Cost  Unit cost (per hour 
unless stated, $Aus) 
Units required per 
site 
Total 
PCC Trainer  60(Bradford 
University, UK)
9 (i.e. 45 / 5 sites)  540 
Post-training support  60(Bradford 
University, UK)
6 (i.e. 30 / 5 sites)  360 




2 x 25 hours  1,350 
   PCC  Total  2,250 




Post-training support  100(Bradford 
University, UK)
16 (i.e. 80 / 5 sites)  1,600 




2 x 25 hours  1,350 




8 hours x 2 
residents per month 
5,184 
   DCM  Total  10,034 
 
Using the average number of residents per site and the results of the CMAI, the total 
number of behaviours averted per site under each of the intervention arms was 
estimated. This information was then used to estimate the incremental costs and 
incremental outcomes (Table 4).  
 
  



































UC +8.4(+7.4)  16.4  N/A N/A N/A  N/A
PCC -5.8(-10.3)  19.8  281(350) 2,250 $8.01 
($6.43) 
N/A




N/A = not applicable 
 
The results indicate that the DCM intervention is subject to what is referred to in the 
economic evaluation literature as “dominance”. That is, relative to PCC, it averts 
fewer negative behaviours and is more costly. This remains the case whether the post-
intervention or follow-up CMAI scores are used.  A less effective and more costly 
intervention is not recommended on efficiency grounds. Therefore, DCM is excluded 
from the incremental component of the economic evaluation. The cost per negative 
behaviour averted in the PCC group relative to UC was $8.01 (post-intervention) and 
$6.43 (at follow-up). 
  
This result remained robust under sensitivity analysis. Under all ranges of model 
values, DCM remained subject to dominance. The cost per behaviour averted for the 
PCC group relative to UC ranged from $6.23 to $9.79 post-intervention, and from 
$5.00 to $7.86 at follow-up, suggesting that different organisational contexts will 
produce different results. However, the differences in the ICER do not suggest DCM 
to be the cost-effective option under any of the circumstances considered here. 
 
  
Table 5: Sensitivity analysis 
 








PCC cost per unit 
improvement* 
Staff time  $27 p/h  $17 p/h  $37 p/h  Yes  PI: $6.23 – $9.79 
FU: $5.00 - $7.86 
Cost of post-
DCM support 
$1,600 $0  $3,200  Yes  N/A 
Cost of post-
PCC support 
$360  $0  $720  Yes  PI: $6.73 - $9.29 
FU: $5.40 - $7.46 
DCM mapping 








* PI = Post-intervention; FU = Follow-up 
 
This evaluation is, to our knowledge, the first to investigate the relative costs of PCC 
and DCM in a dementia care setting. In similar population groups, existing work has 
been done in community settings for occupational therapy[15] and respite for 
carers.[16] However, neither these interventions nor this population group have 
received significant attention in the cost-effectiveness literature. Our results suggest 
that PCC, if properly implemented, can match (and potentially exceed) the positive 
outcomes achieved through the use of DCM and do so at a lower cost. This is an 
important result as it provides decision makers with information which they can use to 
allocate resources to other areas of dementia care and the healthcare sector as a whole, 
while maximising the quality of life (and minimising the rate and level of BPSD) 
experienced by residents of dementia care settings. Such considerations will become 
increasingly important with the future increase in dementia prevalence.[2] There are, 
however, a number of caveats which should be considered alongside this result. 
 
Other cost issues might be significant in assessing the cost-effectiveness of PCC and 
DCM. For example, it has been found that caring for people with dementia-related 
behavioural problems may impact on the morale and turnover of staff.[8] If this is 
true, the potentially substantial costs associated with staff turnover (both in terms of 
‘flag-drop’ costs of recruitment and in the cost of DCM/PCC training) should be 
  
considered in the evaluation of these interventions. We do not know what the long-
term implications are for staff working under some level of continuous distress caused 
by coping with the effects of BPSD on care-recipients/residents as well as themselves. 
BPSD is also likely to result in an intangible effect on the quality of life of members 
of the affected person’s family who observe on a regular basis the distress of their 
loved one with unremitting BPSD [17]. Finally, as with all trials, replication in other 
settings would assist in determining how robust these results are. 
 
We conclude that PCC appears to be a cost-effective method of reducing agitation and 
other behavioural disturbances in nursing home residents with dementia. Results such 
as those reported here, which establish the most cost-effective interventions from 
those available are useful for practitioners and service managers, enabling them to 
choose the best models of care for persons with dementia in different care settings..  
In order to improve both resident and care staff quality of life, future research needs to 
take into account the cost of care associated with staff burden, as carer stress is linked 
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